In recent years, with the rapid development of gene therapy products, the development of gene therapy formulations has gradually become a hotspot in the world of science and research in various of research fields, including oncology. However, gene therapy formulations are different from traditional sterile pharmaceuticals in that they have the special characteristics of large process variability, small production volume, short potency period, and urgent clinical needs, and therefore need to be subjected to rapid aseptic testing of the products. CD Formulation has rich experience in the development of gene therapy formulations, and we have an advanced and comprehensive technology platform for the development of gene therapy formulations. Our research team provides reliable sterility testing support for the quality control of gene therapy formulations.
The production process of gene therapy formulations is complex and susceptible to a variety of factors, and their components are complicated and generally cannot be terminally sterilized. Therefore, strict quality control of gene therapy preparations is a necessary measure to reduce the risk of contamination by exogenous factors or toxic impurities in the products and to ensure their safety and effectiveness.
With the rapid development of biotherapeutic products, traditional sterility testing methods are no longer able to meet the current requirements for speed and efficiency. Therefore, we address this issue by providing rapid sterility testing technical support to provide faster and more reliable test results to ensure product safety and quality. Our rapid sterility testing technologies are based on microbial growth information, direct determination of live microorganisms, and analysis of specific components of microbial cells. These technologies include but are not limited to, bioluminescence, electrochemistry, and flow cytometry. We can provide results in a relatively short period while maintaining high sensitivity and accuracy.
We can provide the following rapid sterile assays.
Design personalized sterility testing solutions according to the characteristics and needs of the customer's products.
Provide methodology validation services in compliance with regulations to ensure the validity and compliance of testing methods.
Establish a high-standard testing service platform to provide services including biosafety testing, methodology development, target validation, and evaluation.
Provide detailed assay reports, including data analysis, result interpretation and recommendations.
Technology: Sterility testing
Journal: J Clin Microbiol
IF: 5.8
Published: 2021
Current sterility testing methods, including USP<71> and blood culture systems, have limitations in detecting fungal contaminants. This study evaluated the iLYM medium, originally used in the food industry, for potential application in ATMP sterility testing. Researchers compared multiple test systems, media formulations, and incubation conditions using fungi from cleanroom environments. Results showed that traditional methods like USP<71> outperformed automated systems, but a dual-bottle combination of iLYM and iFA Plus provided fungal sensitivity comparable to USP<71>, offering a more effective testing approach for both bacterial and fungal contamination.
CD Formulation provides sterility testing services that are critical to ensuring the safety and quality of gene therapy formulations. We can provide customized testing solutions based on the needs of our clients' projects to ensure that we can help them accelerate the development process of their gene therapy formulations. If you are interested in us, please feel free to contact us.
References